NGNE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Neurogene Inc (NGNE) is not a strong buy at this moment for a beginner, long-term investor with $50,000-$100,000 available. While the stock has significant upside potential based on analyst ratings and its clinical progress, insider selling, weak technical indicators, and lack of immediate trading signals suggest caution. The investor may consider monitoring the stock for better entry points or further developments in its clinical trials.
The MACD histogram is negative (-0.14) and contracting, indicating weak momentum. RSI is neutral at 56.562, and moving averages are converging, showing no clear trend. The stock is trading near its pivot level (20.713), with resistance at 22.669 and support at 18.757. Overall, the technical indicators suggest a neutral to slightly bearish trend.
Canaccord initiated coverage with a $200 price target, highlighting significant upside potential.
Neurogene's NGN-401 therapy is progressing well, with clinical trials on track and a potential market launch by
The company is well-capitalized with $269 million in cash reserves, providing operational runway until Q1 2028.
Insider selling has increased by 119.04% over the last month, raising concerns about confidence among company executives.
The stock's technical indicators show weak momentum and no clear bullish signals.
The company reported significant operating and net losses for FY 2025, reflecting financial challenges.
For Q4 2025, Neurogene reported a net income of -$24.735 million, an improvement of 26.76% YoY, and EPS of -1.12, up 12% YoY. However, gross margin dropped to 0, indicating no revenue generation yet. The company remains pre-revenue but has strong cash reserves of $269 million to fund operations through Q1 2028.
Canaccord initiated coverage with a Buy rating and a $200 price target, citing significant upside potential for NGN-401. LifeSci Capital also rated the stock as Outperform with a $50 price target. Analysts see clear upside even with conservative estimates, but the stock remains speculative given its clinical-stage status.
